Literature DB >> 19075069

Continuous cefazolin infusion to treat bone and joint infections: clinical efficacy, feasibility, safety, and serum and bone concentrations.

Valérie Zeller1, Frédérick Durand, Marie-Dominique Kitzis, Luc Lhotellier, Jean-Marc Ziza, Patrick Mamoudy, Nicole Desplaces.   

Abstract

Cefazolin has been used for many years to treat bone and joint infections. Because of its time-dependent antimicrobial activity, continuous infusion would potentially be beneficial. We report on the feasibility, safety, and efficacy of prolonged continuous intravenous cefazolin therapy in a cohort of 100 patients, their serum cefazolin levels, and the concomitant bone cefazolin concentrations in 8 of them. This retrospective cohort study included all the patients treated for bone or joint infection with a continuous cefazolin infusion administered over a 12-h period twice daily for >or=2 weeks. Drug monitoring was performed at least twice for all the patients. Serum and bone cefazolin concentrations were determined by standardized disk diffusion microbiological assays. The absence of clinical, biological, and radiological signs of infection after 2 years of follow-up and the same criteria after 1 year of follow-up defined cures and probable cures, respectively. The median treatment duration was 42 days, and the median daily cefazolin dose was 6 g. Half of the patients received parenteral antibiotic therapy on an outpatient basis. Two moderate-grade adverse events were observed. The median serum cefazolin concentrations were 63 microg/ml (range, 13 to 203 microg/ml) and 57 microg/ml (range, 29 to 128 microg/ml) on days 2 to 10 and days 11 to 21, respectively. The median bone cefazolin concentration reached 13.5 microg/g (range, 3.5 to 29 microg/g). The median bone concentration/serum concentration ratio was 0.25 (range, 0.06 to 0.41). Among 88 patients with a median follow-up of 25 months (range, 12 to 53 months), 52 were considered cured and 29 were considered probably cured. Thus, the treatment of bone and joint infections with a prolonged continuous intravenous cefazolin infusion was feasible, effective, well-tolerated, safe, and convenient, making it a strong candidate for home therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19075069      PMCID: PMC2650516          DOI: 10.1128/AAC.00389-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  The role of anesthesia in surgical mortality.

Authors:  R D DRIPPS; A LAMONT; J E ECKENHOFF
Journal:  JAMA       Date:  1961-10-21       Impact factor: 56.272

Review 2.  Continuous infusion of beta-lactam antibiotics.

Authors:  W A Craig; S C Ebert
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

Review 3.  Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials.

Authors:  Sofia K Kasiakou; George J Sermaides; Argyris Michalopoulos; Elpidoforos S Soteriades; Matthew E Falagas
Journal:  Lancet Infect Dis       Date:  2005-09       Impact factor: 25.071

4.  Assessment of cefazolin and cefuroxime tissue penetration by using a continuous intravenous infusion.

Authors:  J E Connors; J T DiPiro; R G Hayter; K D Hooker; J A Stanfield; T R Young
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

5.  The diffusion of pefloxacin into bone and the treatment of osteomyelitis.

Authors:  P Dellamonica; E Bernard; H Etesse; R Garraffo
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

6.  Antibiotic distribution in normal and osteomyelitic bone.

Authors:  R H Fitzgerald
Journal:  Orthop Clin North Am       Date:  1984-07       Impact factor: 2.472

Review 7.  Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials?

Authors:  Luca Lazzarini; Benjamin A Lipsky; Jon T Mader
Journal:  Int J Infect Dis       Date:  2005-05       Impact factor: 3.623

Review 8.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

Review 9.  Management of infections of osteoarticular prosthesis.

Authors:  J Barberán
Journal:  Clin Microbiol Infect       Date:  2006-05       Impact factor: 8.067

10.  Multicenter collaborative evaluation of a standardized serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis.

Authors:  M P Weinstein; C W Stratton; H B Hawley; A Ackley; L B Reller
Journal:  Am J Med       Date:  1987-08       Impact factor: 4.965

View more
  15 in total

1.  Streptococcal and Staphylococcus aureus prosthetic joint infections: are they really different?

Authors:  Yousra Kherabi; Valérie Zeller; Younes Kerroumi; Vanina Meyssonnier; Beate Heym; Olivier Lidove; Simon Marmor
Journal:  BMC Infect Dis       Date:  2022-06-17       Impact factor: 3.667

2.  Current management of prosthetic joint infections in adults: results of an Emerging Infections Network survey.

Authors:  Jonas Marschall; Michael A Lane; Susan E Beekmann; Philip M Polgreen; Hilary M Babcock
Journal:  Int J Antimicrob Agents       Date:  2013-01-09       Impact factor: 5.283

3.  Continuous clindamycin infusion, an innovative approach to treating bone and joint infections.

Authors:  Valérie Zeller; Arnaud Dzeing-Ella; Marie-Dominique Kitzis; Jean-Marc Ziza; Patrick Mamoudy; Nicole Desplaces
Journal:  Antimicrob Agents Chemother       Date:  2009-10-19       Impact factor: 5.191

4.  Effect of biofilms on recalcitrance of staphylococcal joint infection to antibiotic treatment.

Authors:  Sana Dastgheyb; Javad Parvizi; Irving M Shapiro; Noreen J Hickok; Michael Otto
Journal:  J Infect Dis       Date:  2014-09-11       Impact factor: 5.226

5.  Cathodic Voltage-controlled Electrical Stimulation Plus Prolonged Vancomycin Reduce Bacterial Burden of a Titanium Implant-associated Infection in a Rodent Model.

Authors:  Scott R Nodzo; Menachem Tobias; Richard Ahn; Lisa Hansen; Nicole R Luke-Marshall; Craig Howard; Linda Wild; Anthony A Campagnari; Mark T Ehrensberger
Journal:  Clin Orthop Relat Res       Date:  2016-07       Impact factor: 4.176

6.  Setting up an outpatient parenteral antimicrobial therapy (OPAT) unit in Switzerland: review of the first 18 months of activity.

Authors:  C Gardiol; R Voumard; C Cochet; S de Vallière
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-17       Impact factor: 3.267

7.  Large Cohort Study of Central Venous Catheter Thrombosis during Intravenous Antibiotic Therapy.

Authors:  Stéphanie Guillet; Valérie Zeller; Vincent Dubée; Françoise Ducroquet; Nicole Desplaces; Marie Hélène Horellou; Simon Marmor; Jean Marc Ziza
Journal:  Antimicrob Agents Chemother       Date:  2015-10-12       Impact factor: 5.191

8.  Prescribing Patterns and Patient Outcomes for Bone and Joint Infections Treated with Cefazolin and Probenecid: A Retrospective Observational Study.

Authors:  Marci E Dearing; Sarah V Burgess; Valerie Murphy; Samuel Campbell; Lynn Johnston; Tasha D Ramsey
Journal:  Can J Hosp Pharm       Date:  2020-06-01

9.  Coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerous.

Authors:  Ines Kouki; Clémence Montagner; Wladimir Mauhin; Jonathan London; Thierry Lazard; Sylvie Grimbert; Valérie Zeller; Olivier Lidove
Journal:  J Bone Jt Infect       Date:  2021-04-01

10.  Interactions among osteoblastic cells, Staphylococcus aureus, and chitosan-immobilized titanium implants in a postoperative coculture system: An in vitro study.

Authors:  Niranjan Ghimire; Berit L Foss; Yuyu Sun; Ying Deng
Journal:  J Biomed Mater Res A       Date:  2015-11-09       Impact factor: 4.854

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.